Doctor's office
Enter your doctor's name to get office information.
Find labs in your network
Enter your primary care doctor's name to find labs in your network.
Find urgent care centers in your network
Enter your primary care doctor's name to find urgent care centers in your network.
FollowMyHealth®
Driving Directions
Cart
Update Information
Forgot Password

Please enter your e-mail address.

Sharp Health News

Patients benefit from breakthrough breast cancer drug

Jan. 15, 2020

Patients benefit from breakthrough breast cancer drug

Britta Knight participated in the clinical trial for a new drug therapy for breast cancer while receiving care at Sharp. The U.S. Food and Drug Administration (FDA) recently approved the drug after it showed remarkable benefits for patients.

Sharp HealthCare actively takes part in clinical trials to offer patients new, improved treatments. One such investigational therapy — a new treatment for breast cancer — recently gained U.S. Food and Drug Administration (FDA) approval after showing remarkable benefits for patients with the disease.

Several Sharp HealthCare patients participated in the clinical trial, which showed so much promise in reducing tumors that the FDA deemed the new drug a “breakthrough therapy” during initial phases of the trial.

ENHERTU®, known during the trial as DS-8201, treats patients with a particular type of advanced, aggressive breast cancer. Breast cancer cells in these patients have a gene mutation that makes an excess of a protein called HER2 (human epidermal growth factor receptor 2), which promotes the growth of cancer cells.

About 1 in every 5 women with breast cancer has a type that is HER2-positive. Many of these tumors advance to a point where available therapies can no longer control the disease. The cancer often spreads to other parts of the body.

ENHERTU® is part of a novel class of drugs called antibody-drug conjugates. (Antibodies are proteins made by the body that fight off foreign substances.) The treatment works by attaching chemotherapy to an antibody designed to only bond to cells containing the HER2 protein. Once the drug combination attaches to a breast cancer cell, the chemotherapy is released inside the cell to kill it.

This type of targeted treatment may also reduce the side effects from traditional chemotherapy that can affect both cancerous and noncancerous cells.

“This is a very promising therapy for patients with this type of breast cancer,” says Dr. Charles Redfern, a medical oncologist at Sharp Memorial Hospital and a clinical investigator on the trial. “It has shown an impressive response rate in patients that had an average of seven previous treatments for advanced disease.”

Britta Knight was one such patient who benefited from the treatment. Knight was just 33 years old when she found out she had stage 4 breast cancer in December 2015.

“It started with pain in my left breast that definitely didn’t feel right. It felt like someone was sticking pins and needles in my breast,” says Britta, who is being treated by Dr. Reema Batra, a medical oncologist at Sharp Grossmont Hospital and one of the other clinical investigators.

“Breast cancer can happen at any age, but fewer than 10% of women are diagnosed in their 30s,” says Dr. Batra. “In those instances, the disease is more likely late-stage and tends to be more aggressive.” After meeting specific criteria and exhausting other existing therapies, Britta began her clinical trial in March 2018.

“Dr. Batra was my ally. She sat down with the tumor board and told them about me, and that’s how I got started,” she says.

The treatment was effective, with few side effects, and Britta’s cancer is now in remission. Her scans have shown no sign that the cancer has spread, and she’s maintaining a high quality of life.

“When they brought the idea of a clinical trial to me, I said ‘Let’s do it!’ I thought the worse that could happen is that it wouldn’t work,” she says. “But it has, and I feel like I’m part of something bigger that’s going to make a difference in the lives of women everywhere.”

“Sharp HealthCare was the only health system in the western part of the United States that participated in phase 1 of the clinical trial,” says Dr. Redfern. “Patients traveled from as far away as Canada to participate in the study at Sharp.”

In addition to HER2-positive breast cancer, ENHERTU is being studied in many other cancers with HER2 expression, including lung, colon and stomach cancer.

“It’s OK to be afraid if you have breast cancer, but remain positive and don’t lose hope. There’s so many scientific advances now to help, and I’m grateful to my family and health care team for all the support I’ve received,” says Britta.

Learn more about cancer clinical trials available at Sharp HealthCare.

For the news media: To talk with Dr. Charles Redfern about breast cancer clinical trials or Dr. Reema Batra about breast cancer treatments at Sharp HealthCare for an upcoming story, contact Erica Carlson, senior public relations specialist, at erica.carlson@sharp.com.

You might also like:

Choose the doctor who's right for you.

At Sharp, we make it easy to find an exceptional doctor — right where you live and work.

All Categories
Contact Sharp HealthCare
Call us

1-800-827-4277

If this is a life- or limb-threatening emergency, please call 911 immediately.


Email us

Please do not use this form to convey personal or medical information.

How would you like to be contacted?
Date of birth
Optional


Find other numbers

View our phone directory

What's This?

These important numbers are located on your billing statement.

Find your Sharp Rees-Stealy account number

Find your Sharp Rees-Stealy account number

Find your Sharp hospital account number

Find your Sharp hospital account number

Find your SharpCare account number

Find your SharpCare account number
What's GDPR?

The General Data Protection Regulation (GDPR) governs the processing of personal information gathered from individuals while they are in the European Union (EU) and parts of the EEA (European Economic Area, which currently includes Iceland, Lichtenstein and Norway).

We are sorry, but we are unable to process hospital price estimates if you live or are travelling within the EU or affiliated nations.

To learn more, call us at 858-499-5901.

What's This?

Many surgery and procedure names sound similar. If possible, please provide the current procedure terminology (CPT) code, which can be found on the order from your doctor.

If you cannot provide the CPT code, please contact your doctor's office for the CPT or a detailed description of services.